A matched couple: Combining kinase inhibitors with immunotherapy for cancer treatment.
Small-molecule kinase inhibitors targeting oncogenic signaling pathways have been explored as cancer therapeutic agents due to their strong anti-tumor activity and manageable toxicity. Accumulating evidence shows that many kinase inhibitors also profoundly modulate immune cell functions, suggesting they may be promising candidates for combination with immunotherapeutic agents for the improved treatment of cancer.
Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick MD, USA 21702.
Qun
Q
Jiang
Jonathan M
JM
Weiss
Robert H
RH
Wiltrout